Reported Earlier, Ultragenyx And Mereo BioPharma Announced Interim Phase 2 Data From Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates In Patients With Osteogenesis Imperfecta
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx and Mereo BioPharma have announced interim Phase 2 data from their Phase 2/3 Orbit study. The data shows that Setrusumab significantly reduced fracture rates in patients with Osteogenesis Imperfecta.
October 16, 2023 | 6:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mereo BioPharma's partnership with Ultragenyx in the development of Setrusumab has yielded positive results, which could potentially boost the company's stock.
Positive clinical trial results often lead to increased investor confidence and can drive up a company's stock price. Given the significance of these results, it's likely that Mereo BioPharma's stock will see a positive impact.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Ultragenyx's Setrusumab has shown significant results in reducing fracture rates in Osteogenesis Imperfecta patients, which could potentially boost the company's stock.
Positive clinical trial results often lead to increased investor confidence and can drive up a company's stock price. Given the significance of these results, it's likely that Ultragenyx's stock will see a positive impact.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50